home / stock / bcyp / bcyp quote
Last: | $ |
---|---|
Change Percent: | 31.20% |
Open: | $0.01312 |
Close: | $0.01312 |
High: | $0.01312 |
Low: | $0.01312 |
Volume: | 714 |
Last Trade Date Time: | 12/05/2019 04:14:54 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$ | $0.01312 | $0.01312 | $0.01312 | $0.01312 | 714 | 12-05-2019 |
$ | $0.01 | $0.01 | $0.01 | $0.01 | 12,000 | 12-04-2019 |
$ | $N/A | $0.01 | $N/A | $N/A | 0 | 12-03-2019 |
$ | $N/A | $0.01 | $N/A | $N/A | 0 | 12-02-2019 |
$ | $N/A | $0.01 | $N/A | $N/A | 0 | 11-29-2019 |
$ | $N/A | $0.01 | $N/A | $N/A | 0 | 11-28-2019 |
$ | $N/A | $0.01 | $N/A | $N/A | 0 | 11-27-2019 |
$ | $0.01 | $0.01 | $0.01 | $0.01 | 80,331 | 11-26-2019 |
$ | $N/A | $0.014 | $N/A | $N/A | 0 | 11-25-2019 |
$ | $N/A | $0.014 | $N/A | $N/A | 0 | 11-22-2019 |
$ | $N/A | $0.014 | $N/A | $N/A | 66 | 11-21-2019 |
$ | $0.012 | $0.014 | $0.014 | $0.012 | 28,000 | 11-20-2019 |
$ | $N/A | $0.0125 | $N/A | $N/A | 0 | 11-19-2019 |
$ | $N/A | $0.0125 | $N/A | $N/A | 0 | 11-18-2019 |
$ | $N/A | $0.0125 | $N/A | $N/A | 34 | 11-15-2019 |
$ | $N/A | $0.0125 | $N/A | $N/A | 0 | 11-14-2019 |
$ | $N/A | $0.0125 | $N/A | $N/A | 0 | 11-13-2019 |
$ | $N/A | $0.0125 | $N/A | $N/A | 0 | 11-12-2019 |
$ | $N/A | $0.0125 | $N/A | $N/A | 0 | 11-11-2019 |
$ | $N/A | $0.0125 | $N/A | $N/A | 0 | 11-08-2019 |
News, Short Squeeze, Breakout and More Instantly...
SAB Biotherapeutics Inc Com Company Name:
BCYP Stock Symbol:
OTCMKTS Market:
SAB Biotherapeutics Inc Com Website:
SIOUX FALLS, S.D., Aug. 21, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics ( Nasdaq: SABS ), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human immunoglobulins (hIgG), also known as fully-human...
SAB highlights results from GLP toxicology study confirming SAB-142's mechanism of action at the 23rd Federation of Clinical Immunology Societies (FOCIS) Study shows SAB’s fully-human multi-target immune modulating therapeutic for treatment of Type 1 Diabetes is well tolerated ...
SIOUX FALLS, S.D., May 30, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS ), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human immunoglobulin (hIgG) antibodies (fully-human polyc...